JYNTHIGH SIGNALFINANCIAL10-K

The Joint Corp experienced a dramatic deterioration in operating cash flow alongside significant balance sheet contraction despite revenue growth.

The massive decline in operating cash flow from $9.4M to $1.8M represents a critical deterioration in the company's ability to generate cash from operations, raising immediate concerns about working capital management and operational efficiency. This cash flow compression occurred despite 15.5% revenue growth, suggesting underlying operational challenges that investors should monitor closely.

Comparing 2026-03-13 vs 2025-03-14View on EDGAR →
FINANCIAL ANALYSIS

JYNT delivered mixed financial results with revenue growing a solid 15.5% to $117.7M and operating losses improving modestly, but these positives were overshadowed by severely weakened cash generation. The company's balance sheet contracted meaningfully across most categories, with total assets declining 24.2% to $61.0M and current assets falling 27.8%, though total debt was substantially reduced. The dramatic operating cash flow deterioration despite revenue growth signals potential working capital or operational execution issues that warrant investor attention.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-80.5%
$9.4M$1.8M

Operating cash flow fell 80.5% — earnings quality concerns; investigate working capital changes and non-cash items.

Total Debt
Balance Sheet
-69.8%
$332K$100K

Debt reduced 69.8% — deleveraging strengthens balance sheet and reduces financial risk.

Operating Income
P&L
+48%
-$1.8M-$913K

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Current Liabilities
Balance Sheet
-33.5%
$49.4M$32.8M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
-27.8%
$72.2M$52.1M

Current assets declined 27.8% — monitor working capital adequacy and short-term liquidity.

Capital Expenditure
Cash Flow
+26.8%
$1.2M$1.5M

Capex increased 26.8% — ongoing investment in capacity or infrastructure for future growth.

Total Liabilities
Balance Sheet
-26.6%
$62.5M$45.9M

Liabilities reduced 26.6% — deleveraging improves balance sheet strength and financial flexibility.

Total Assets
Balance Sheet
-24.2%
$80.4M$61.0M

Total assets contracted 24.2% — asset sales, write-downs, or balance sheet optimization underway.

Stockholders Equity
Balance Sheet
-16%
$17.9M$15.1M

Equity decreased 16% — buybacks or losses reducing book value, monitor solvency ratios.

Revenue
P&L
+15.5%
$101.9M$117.7M

Revenue growing 15.5% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2026-03-13
PRIOR — 2025-03-14
ADDED
There were 14,114,334 shares of the registrant s common stock outstanding as of March 9, 2026.
We delivered over 14.4 million patient visits in 2025, down from 14.7 million patient visits in 2024, generating over $532.4 million and $530.3 million of system-wide sales, respectively, across our highly franchised network.
We will continue the franchise-focused expansion of chiropractic clinics in key markets throughout North America and potentially abroad.
Since acquiring the predecessor to our company in March 2010, we have grown our enterprise from eight to 960 clinics in operation as of December 31, 2025, with an additional 82 franchise licenses sold but not yet developed across our network, and 57 letters of intent for 57 future clinic licenses.
As of December 31, 2025, our franchisees owned or managed 885 clinics, and we owned or managed 75 clinics.
+7 more — sign up free →
REMOVED
There were 15,174,931 shares of the registrant s common stock outstanding as of March 10, 2025.
We delivered over 14.7 million patient visits in 2024, up from 13.6 million patient visits in 2023, generating over $530.3 million and $488 million of system-wide sales, respectively, across our highly franchised network.
We will continue the rapid and franchise focused expansion of chiropractic clinics in key markets throughout North America and potentially abroad.
Since acquiring the predecessor to our company in March 2010, we have grown our enterprise from eight to 967 clinics in operation as of December 31, 2024, with an additional 92 franchise licenses sold but not yet developed across our network, and 53 letters of intent for 53 future clinic licenses.
As of December 31, 2024, our franchisees owned or managed 842 clinics, and we owned or managed 125 clinics.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →